BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.
Related Questions
How will BriaCell’s acceptance into MSK’s Therapeutics Accelerator affect BCTX’s short‑term stock momentum?
What are the expected milestones and timelines for Bria‑OTS+ in metastatic breast and prostate cancer trials?
Will the Accelerator program provide additional funding or resources, and how will that impact BriaCell’s cash runway?
How does Bria‑OTS+ compare to existing off‑the‑shelf immunotherapies from competitors like TCR‑based or CAR‑T platforms?
What potential regulatory pathways (e.g., Fast Track, Breakthrough Therapy) could accelerate Bria‑OTS+ approval?
Could the partnership with MSK lead to co‑development agreements or revenue‑sharing that affect future earnings?
What is the anticipated market size for Bria‑OTS+ in the indicated cancer indications?
Will the inclusion in the Accelerator program trigger any dilution from new equity issuances or convertible securities?
How might this news influence analyst coverage, target price revisions, or consensus estimates for BriaCell?
Are there any risks or contingencies disclosed that could delay or derail the clinical development of Bria‑OTS+?